Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$1.56 - $2.93 $1.59 Million - $2.98 Million
-1,018,244 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$2.91 - $4.83 $438,208 - $727,335
150,587 Added 17.36%
1,018,244 $3.06 Million
Q2 2021

Aug 16, 2021

BUY
$4.17 - $5.74 $1.55 Million - $2.14 Million
371,957 Added 75.04%
867,657 $4.05 Million
Q1 2021

May 17, 2021

BUY
$5.28 - $9.64 $88,962 - $162,424
16,849 Added 3.52%
495,700 $2.62 Million
Q4 2020

Feb 16, 2021

BUY
$5.75 - $7.13 $61,657 - $76,454
10,723 Added 2.29%
478,851 $3.12 Million
Q3 2020

Nov 16, 2020

BUY
$4.9 - $7.12 $971,743 - $1.41 Million
198,315 Added 73.5%
468,128 $2.86 Million
Q2 2020

Aug 17, 2020

BUY
$6.43 - $9.86 $587,695 - $901,194
91,399 Added 51.23%
269,813 $1.96 Million
Q1 2020

May 15, 2020

BUY
$6.36 - $10.05 $617,002 - $974,980
97,013 Added 119.18%
178,414 $1.24 Million
Q4 2019

Feb 14, 2020

SELL
$8.49 - $12.81 $2.08 Million - $3.14 Million
-245,173 Reduced 75.07%
81,401 $718,000
Q3 2019

Nov 14, 2019

SELL
$5.58 - $14.47 $29,758 - $77,168
-5,333 Reduced 1.61%
326,574 $3.66 Million
Q2 2019

Aug 13, 2019

BUY
$5.22 - $9.08 $756,383 - $1.32 Million
144,901 Added 77.48%
331,907 $2.01 Million
Q1 2019

May 14, 2019

BUY
$5.35 - $9.82 $617,925 - $1.13 Million
115,500 Added 161.52%
187,006 $1.47 Million
Q4 2018

Feb 14, 2019

SELL
$3.43 - $6.19 $1,372 - $2,476
-400 Reduced 0.56%
71,506 $355,000
Q3 2018

Nov 14, 2018

SELL
$4.75 - $14.5 $50,350 - $153,700
-10,600 Reduced 12.85%
71,906 $342,000
Q2 2018

Aug 14, 2018

BUY
$13.3 - $17.45 $1.1 Million - $1.44 Million
82,506 New
82,506 $1.12 Million

Others Institutions Holding LCI

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About LANNETT CO INC


  • Ticker LCI
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 42,960,000
  • Market Cap $1.29M
  • Description
  • Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nas...
More about LCI
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.